STOCK TITAN

PROCEPT BioRobotics to Report Third Quarter 2023 Financial Results on November 1, 2023

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings
Rhea-AI Summary
PROCEPT BioRobotics to report Q3 2023 financial results
Positive
  • Investors can listen to the conference call for Q3 2023 financial results on November 1, 2023
  • Live audio of the webcast will be available on the Company's website
Negative
  • None.

SAN JOSE, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the third quarter of 2023 after market close on Wednesday, November 1, 2023. The Company’s management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time.

Investors interested in listening to the conference call may do so by following one of the below links:

Live audio of the webcast will be available on the “Investors” section of the Company’s website at: https://ir.procept-biorobotics.com.

An archived recording will be available on the “Investors” section of the Company’s website at: https://ir.procept-biorobotics.com. Each webcast will be available for replay for at least 90 days after the event.

About PROCEPT BioRobotics Corporation
PROCEPT BioRobotics is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. PROCEPT BioRobotics develops, manufactures and sells the AquaBeam Robotic System, an advanced, image-guided, surgical robotic system for use in minimally invasive urologic surgery with an initial focus on treating benign prostatic hyperplasia, or BPH. BPH is the most common prostate disease and impacts approximately 40 million men in the United States. PROCEPT BioRobotics designed Aquablation therapy to deliver effective, safe and durable outcomes for males suffering from lower urinary tract symptoms, or LUTS, due to BPH that are independent of prostate size and shape or surgeon experience. The Company has developed a significant and growing body of clinical evidence, which includes nine clinical studies and over 150 peer-reviewed publications, supporting the benefits and clinical advantages of Aquablation therapy.

Investor Contact:
Matt Bacso
VP, Investor Relations and Business Operations
m.bacso@PROCEPT-BioRobotics.com


FAQ

When will PROCEPT BioRobotics report its Q3 2023 financial results?

PROCEPT BioRobotics will report its Q3 2023 financial results after market close on November 1, 2023.

How can investors listen to the conference call for Q3 2023 financial results?

Investors can listen to the conference call by following the webcast link provided or by dialing in using the registration link for sell-side research analysts.

Where can I find the live audio of the webcast?

The live audio of the webcast will be available on the 'Investors' section of the Company's website.

How long will the webcast be available for replay?

Each webcast will be available for replay for at least 90 days after the event.

PROCEPT BioRobotics Corporation

NASDAQ:PRCT

PRCT Rankings

PRCT Latest News

PRCT Stock Data

4.52B
52.18M
4.9%
86.94%
12.91%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States of America
SAN JOSE